Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials
A. Tiede; F. Abdul‐Karim; M. Carcao; P. Persson; W. H. O. Clausen; S. Kearney; T. Matsushita; C. Negrier; J. Oldenburg; E. Santagostino; G. Young
Author Information: Clinic for Haematology, Haemostaseology, Oncology and Stem Cell Transplantation
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.